Taisho To Enter Lactic Acid Market With Biofermin Acquisition
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Taisho Pharmaceutical will take its first steps into the lactic acid bacteria drugs market following its proposed acquisition of Kobe, Japan-based Biofermin Pharmaceutical, approved by the latter's board Feb. 12